Sign in
CompletedNo phase

Single Cell Sequencing of Tonsillar Tissue in Children With OSA

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
16 people enrolled
Started
1 Jan 2023
Ended
30 Jun 2026
Type of study
Observational, 2 groups
Treatments tested
  • Tonsillectomy
Record updated
23 October 2026

Who can take part

Age
6 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Case: Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases
  • Control: Non-OSA subjects (with PSG OAHI <1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis

Who cannot take part

  • Previous upper airway surgery, genetic or syndromal disease, congenital or acquired neuromuscular disease, congenital or acquired immunodeficiency, known metabolic syndrome, craniofacial abnormalities

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Obstructive sleep apnoea (OSA) in children is a prevalent sleep disorder, and is characterised by repetitive complete or partial upper airway obstruction during sleep. It is an important disease as it is associated with a large spectrum of end-organ morbidities.

Read full original descriptionShow less

Adenotonsillar hypertrophy is the commonest cause of OSA in children, however, the cause of the lymphoid tissue hypertrophy in some individuals but not the others remains unknown. To address the cellular heterogeneity and immune cell involvement in adenotonsillar hypertrophy, here, we propose to employ single-cell sequencing analysis to identify the cell-specific expression patterns associated with the disease, which will enhance our understanding of the pathogenesis of tonsillar hypertrophy in children with OSA and may provide directions for development of novel therapy.

The 2 groups in the trial

  • OSA case

    Chinese children aged 6-11 years old with habitual snoring (≥3 nights per week) and polysomnography (PSG) confirmed OSA (obstructive apnoea hypopnoea index (OAHI) of ≥1/hour), with adenotonsillar hypertrophy and clinical indications for adenotonsillectomy will be recruited as cases.

    Treatment: Tonsillectomy

  • Control

    Non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.

    Treatment: Tonsillectomy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Single Cell Sequencing to Examine the Pathogenesis of Adenotonsillar Hypertrophy in Children With Obstructive Sleep Apnoea
Record updated
23 October 2026